Bispyribac

430.37

430.37

603-065-9

9W20BD966G

DTXSID0043977

White powder

2933599013

144

1.25 (est)

white crystal powder

1.379±0.06 g/cm3(Predicted)

148-150 °C

686.4±65.0 °C(Predicted)

368.9ºC

In water, 3.44X10+3 mg/L at 25 deg C (est)

Do not contaminate water, food or feed by storage or disposal. Store in a cool dry place. Keep pesticide in original container. Keep container closed when not in use. Do not put concentrate or dilute into food or drink containers. Not for use or storage in or around the home. /Bispyribac-sodium; Regiment Herbicide/

1.54X10-11 mm Hg at 25 deg C (est)

Henry's Law constant = 1.07X10-16 atm-cu m/mol at 25 °C (est)

pKa = 1.99 (est)

White odorless powder. MP: 223-224 °C; VP: 5.05X10-6 mPa at 25 °C. log Kow = -1.03 at 23 °C. Henry's Law constant = 3X10-11 Pa-cu m/mol (calc); Density: 1.47. Solubility in distilled water = 68.7 g/L at 20 °C. Solubility in methanol 25 g/L at 20 °C; in ethyl acetate 6.1X10-2, n-hexane 8.34X10-3, acetone 1.4, toluene <1.0X10-6, dichloromethane 1.2 (all in mg/L, 25 °C). pKa = 3.35 at 20 °C. Technical formulation is >93% /Bispyribac sodium/|Decomposes at 223 °C. Hydrolysis half-life >1 year at pH 7 and 9, 25 °C, 88 days pH 4, 25 °C. Aqueous photolysis half-life = 42 days in natural water, 499 days in distilled water (both 25 °C, 1.53 W/sq m, 250-365 nm) /Bispyribac sodium/|Hydroxyl radical reaction rate constant = 1.49X10-10 cu cm/molec-sec at 25 °C (est)

Decomposes at 223 deg C. Hydrolysis DT50 >1 year (pH7 and 9, 25 deg C), 88 days (pH 4, 25 deg C).

SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational harm/injury/toxicity or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal and plant life; and conformance with environmental and public health regulations.|Do not reuse the outer bag. Dispose of outer bag in a sanitary landfill, or by incineration, or if allowed by state and local authorities, by burning. If burned, stay out of smoke. /Bispyribac-sodium; Regiment Herbicide/|Waste resulting from the use of this product may be disposed of on site or at an approved waste disposal facility. /Bispyribac-sodium; Regiment Herbicide/|SRP: Wastewater from contaminant suppression, cleaning of protective clothing/equipment, or contaminated sites should be contained and evaluated for subject chemical or decomposition product concentrations. Concentrations shall be lower than applicable environmental discharge or disposal criteria. Alternatively, pretreatment and/or discharge to a permitted wastewater treatment facility is acceptable only after review by the governing authority and assurance that "pass through" violations will not occur. Due consideration shall be given to remediation worker exposure (inhalation, dermal and ingestion) as well as fate during treatment, transfer and disposal. If it is not practicable to manage the chemical in this fashion, it must be evaluated in accordance with EPA 40 CFR Part 261, specifically Subpart B, in order to determine the appropriate local, state and federal requirements for disposal.

Applicators and other handlers must wear: longsleeved shirt and long pants, chemical-resistant gloves such as Barrier Laminate or Butyl Rubber > 14 mils or Nitril Rubber > or = 14 mils or Viton > or = 14 mils, shoes plus socks. /Bispyribac-sodium; Regiment Herbicide/|Approved respirator, chemical-resistant gloves, protective eyewear. /Bispyribac-sodium/|... Restricted-entry interval (REI) of 12 hours. Personal protective equipment (PPE) required for early entry to treated areas that is permitted under the Worker Protection Standard and that involves contact with anything that has been treated, such as plants, soil, or water is: Coveralls, Chemical resistant gloves, such as Barrier Laminate or Butyl Rubber > or = 14 mils or Nitril Rubber > or = 14 mils or Viton > or = 14 mils and shoes plus socks. /Bispyribac-sodium; Regiment Herbicide/|Unless ventilation is adequate to keep airborne concentrations below recommended exposure standards, approved respiratory protection should be worn. /Bispyribac-sodium; Regiment Herbicide/|Eye contact can be avoided by wearing protective eyewear. /Bispyribac-sodium; Regiment Herbicide/

Products of combustion from fires involving this material may be toxic. Avoid breathing smoke and mists. Avoid personnel and equipment contact with fallout and runoff. Minimize the amount of water used for fire fighting. Do not enter any enclosed area without full protective equipment, including self-contained breathing equipment. Contain and isolate runoff and debris for proper disposal. Decontaminate personal protective equipment and fire fighting equipment before reuse. /Bispyribac-sodium; Regiment Herbicide/|Fire Extinguishing Media: Water, dry chemical powder, foam, or CO2. /Bispyribac-sodium/

FOR SPILLS IN WATER: CONTAINMENT: This material will disperse or dissolve in water. Stop the source of the release. Contain and isolate to prevent further release into soil, surface water and ground water. CLEANUP: Clean up spill immediately. Absorb spill with inert material. Remove contaminated water for treatment or disposal. /Bispyribac-sodium; Regiment Herbicide/|FOR SPILLS ON LAND: CONTAINMENT: Reduce airborne dust. Avoid runoff into storm sewers or other bodies of water. CLEANUP: Clean up spill immediately. Vacuum or sweep up material and place in a chemical waste container. Wash area with soap and water. Pick up wash liquid with additional absorbent and place in a chemical waste container. /Bispyribac-sodium; Regiment Herbicide/|Do not contaminate water by cleaning of equipment or disposal of equipment washwaters. /Bispyribac-sodium; Regiment Herbicide/

Use this product only in accordance with its labeling and with the Workers Protection Standard, 40 CFR part 170. /Bispyribac-sodium; Regiment Herbicide/|Follow manufacturer's instructions for cleaning/maintaining personal protective equipment (PPE). If no such instructions for washables, use detergent and hot water. Keep and wash PPE separately from other laundry. /Bispyribac-sodium; Regiment Herbicide/|Boots /Bispyribac-sodium/|This product is toxic to non-target plants. For terrestrial uses, do not apply directly to water, or to areas where surface water is present or to intertidal areas below the mean high water mark. /Bispyribac-sodium; Regiment Herbicide/|For more Preventive Measures (Complete) data for Bispyribac (8 total), please visit the HSDB record page.

LC50 Rat inhalation >4.48 mg/L/4 hr|LD50 Rat dermal >2000 mg/kg|LD50 Rat oral (female) 2635 mg/kg|LD50 Rat oral (male) 4111 mg/kg

Bispyribac's production may result in its release to the environment through various waste streams; its use in the salt form as a herbicide(1) will result in its direct release to the environment(SRC).

TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 1.7X10+4(SRC), determined from a structure estimation method(2), indicates that bispyribac is expected to be immobile in soil(SRC). However, the estimated pKa of bispyribac is 1.99(3), indicating that this compound will almost entirely exist in the anion form in the environment and anions generally do not adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4). Volatilization from moist soil is not expected because the compound exists as an anion and ions do not volatilize. Bispyribac is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 1.5X10-11 mm Hg at 25 °C(SRC), determined from a fragment constant method(5). Biodegradation data were not available(SRC, 2011).|AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 1.7X10+4(SRC), determined from a structure estimation method(2), indicates that bispyribac is expected to adsorb to suspended solids and sediment(SRC). An estimated pKa of 1.99(3) indicates bispyribac will exist almost entirely in the anion form at pH values of 5 to 9 and therefore volatilization from water surfaces is not expected to be an important fate process(SRC). According to a classification scheme(4), an estimated BCF of 3(SRC), from an estimated log Kow of 1.25(5) and a regression-derived equation(6), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Biodegradation data were not available(SRC, 2011).|ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), bispyribac, which has an estimated vapor pressure of 1.5X10-11 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase bispyribac may be removed from the air by wet or dry deposition(SRC). Bispyribac contains chromophores that absorb at wavelengths >290 nm(3), and therefore may be susceptible to direct photolysis by sunlight(SRC).

Bispyribac is not expected to undergo hydrolysis in the environment due to the lack of functional groups that hydrolyze under environmental conditions(1). Bispyribac contains chromophores that absorb at wavelengths >290 nm(1), and therefore may be susceptible to direct photolysis by sunlight(SRC).

An estimated BCF of 3 was calculated in fish for bispyribac(SRC), using an estimated log Kow of 1.25(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC).

Using a structure estimation method based on molecular connectivity indices(1), the Koc of bispyribac can be estimated to be 1.7X10+4(SRC). According to a classification scheme(2), this estimated Koc value suggests that bispyribac is expected to be immobile in soil. However, the estimated pKa for bispyribac is 1.99(3), indicating that this compound will exist almost entirely in the anion form in the environment and anions generally do not adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4).

The estimated pKa of 1.99(1) indicates bispyribac will exist almost entirely in the anion form at pH values of 5 to 9 and therefore volatilization from water surfaces is not expected to be an important fate process. Bispyribac is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 1.5X10-11 mm Hg(SRC), determined from a fragment constant method(2).

Occupational exposure to bispyribac may occur through inhalation and dermal contact with this compound at workplaces where bispyribac is produced or used. (SRC)

Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)

A series of rat metabolism studies with [14CPy]-bispyribac-sodium and [14C-Bn]-bispyribac-sodium indicated that pretreatment, dose level, sex and position of the radiolabel made little effect on the absorption, distribution, elimination and metabolism. It was readily absorbed by male and female rats following intravenous or oral dosing. The total recovery of the administered radioactivity was 95.8-101.6% for all treatment groups. Most of the dose (>43%) of the administered dose was excreted in feces within 48 hours and essentially complete within 5 days. Less than 2% of the administered dose remained in the carcass and tissues and <0.1% of the dose was recovered in air.|Five Fischer 344 rats/sex/group were dosed orally with either 10 or 100 mg/kg of (14)C (Py) KIH-2023 (specific activity: 1.46 GBq/mmol, radiochemical purity: 97.7%, lot no. CP-1221) following overnight fasting. Bispyribac (KIH-2023, purity: 95.2%, lot no. G35-04) was used in the preparation of the dosing solutions. Bile was collected hourly through the first 6 hrs post-dose and at the 6-12 and 12-24 hr intervals. Urine and feces were collected at 0-6, 6-12 and 12-24 hr intervals post-dose. The percentage of the administered dose recovered in the bile over the first 24 hrs after dosing was approximately 36 to 37% for the males and 24 to 27% for the females at the two dose levels. In that first 24 hrs, 2.4% or less of the dose was recovered in the feces. However, at 24 hrs, 22.5 to 30.0% of the radiolabel at the low dose and 40 to 44% at the high dose was still associated with the tissues of the gastrointestinal tract and may not have been absorbed. Only two of the five major radiolabeled moieties in the bile were identified, demethylated Bispyribac and Bispyribac. These two moieties constituted 52.0 to 60.1% of the recovered radiolabel in the bile. Overall, the data indicate that the hepato-biliary pathway is a significant route for the uptake and excretion of the test material.|One Fischer 344 rat/sex/group was dosed by either oral gavage or intravenous injection with 100 mg/kg of (14)C Bispyribac (KIH-2023, specific activity: 1.50 GBq/mmol, radiochemical purity: 98.2%) (label on the 2nd carbon of the pyrimidine ring). Technical grade Bispyribac (KIH-2023, purity: 95.2%) was used to supplement the dosing preparations. Carbon dioxide was collected up to 24 hrs post-dose. Urine and feces were collected at the 0-12, 12-24, 24-48 and 48-72 hr intervals. In phase B, two rats/sex were dosed by oral gavage with 100 mg/kg of the test material. At 15 and 30 minutes and 1, 2, 4, 8, 24, and 48 hrs post-dose, blood was collected by retroorbital bleeding from one male and one female. In phase C, two rats/sex were dosed by oral gavage with 100 mg/kg of the test material. One animal/sex was euthanized by exsanguination at 2 and 72 hrs post-dose. Blood was collected along with specified tissues. In phase E, one male was treated by oral gavage with 100 mg/kg of the test material. Urine and feces were collected over 0-24 and 24-48 hr intervals post-dose for metabolite analysis. When the test material was dosed orally, a greater percentage of the dose was recovered in the feces. Intravenous injection resulted in a lower percentage of radiolabel recovered in the feces with a corresponding increase in recovery from the urine. The presence of the radiolabel in the feces after intravenous dosing indicated that biliary excretion had occurred. Recovery of radiolabeled carbon dioxide was negligible. Peak blood levels were evident at 2 hrs post-dose. The highest levels of radiolabel recovered in the 2 hr samples were in the contents of the gastrointestinal tract. Otherwise, the level of radiolabeling in the tissues had largely dissipated by 72 hrs. The predominant radioalabeled moiety in both the urine and feces was the parent compound. It constituted 86% of the recovered label. ...|Groups of Fischer 344 rats were dosed orally by gavage or by intravenous injection with bis-(pyrimidine-2-(14)C) Bispyribac (KIH-2023, radiochemical purity: 98.3%, specific activity: 87.0 :Ci/mg) ((14)C (Py) Bispyribac) or U-(benzene-(14)C) Bispyribac (radiochemical purity: >99%, specific activity: 50 :Ci/mg) (14)C (Bn) Bispyribac). In Groups 1A, B, C and D, 5 animals/sex/group were dosed orally with 30 mg/kg of either (14)C (Py) Bispyribac (A and C) or (14)C (Bn) Bispyribac (B and D). For Groups 2 A and B, 5 animals/sex/group were dosed daily by oral gavage with 30 mg/kg of Bispyribac, technical grade (purity: 97.2%) for 14 days, followed a dose of 30 mg/kg of either (14)C (Py) Bispyribac (A) or (14)C (Bn) Bispyribac (B). For Groups 3A, B, C and D, 5 animals/sex/group were dosed orally by gavage with 600 mg/kg of either (14)C (Py) Bispyribac (A and C) or (14C) (Bn) Bispyribac (B and D). For Groups 4A, B, C and D, five animals/sex/group received intravenous injections of 30 mg/kg of either (14)C (Py) Bispyribac (A and C) or (14)C (Bn) Bispyribac (B and D). For all groups designated A or B, urine and feces samples were collected at 0-12 hr, 12-24 hr, 24-48 hr, 48-72 hr, 72-96 hr and 96-120 hours post-dose. At that time the animals were euthanized, a blood sample collected and the animals dissected for specified tissues. For all groups designated C or D, blood was collected from the tail vein at 0.25, 0.5, 1, 2, 4, 8, 24, 48, 72 and 96 hours post-dose. At 120 hrs, the animals were euthanized and a blood sample collected. The feces were the primary route of excretion for both of the radiolabeled compounds. At the lower dose, the males excreted from 11 to 13% and 80 to 85% of the administered dose in the urine and feces, respectively. At the higher dose, excretion in the urine ranged from 25 to 28% of the administered dose. In the feces, 70% of the dose was excreted. For the females, the percentage of administered dose excreted by either route did not vary at both dose levels. The percent of administered dose excreted in the urine ranged from 28 to 37%. For the feces, the range was from 48 to 60% (note: two of the radiolabel recovery values from the feces, for Groups 1A and 2A, were close to or in excess of 100% of the administered dose and appeared to be at variance from all of the other data collected). At the lower dosing level via the oral route, peak plasma levels were achieved within 30 minutes of dosing for both radiolabeled compounds. At 600 mg/kg, the plasma levels remained at a peak concentration for up to 4 hrs post-dose. ... The liver, intestinal tract and plasma were the primary sites of recovery of radiolabel at 120 hrs post-dose. Analysis of the radiolabeled material revealed the unmetabolized test compound was the primary moiety excreted. This moiety constituted 68.5 to 82.9% of the administered dose recovered from both the feces and urine (note: the value for the 3B females of 99.8% was well in excess of all of the other recoveries). The quantity of administered dose, sex of the treated animal or the route of treatment did not greatly alter the percent of unmetabolized test material recovered. ...|Absorption, distribution and metabolism of Bispyribac-sodium (sodium 2,6-bis(4,6-dimethoxypyrimidin-2-yloxy)benzoate) or (KIH-2023) in rats orally dosed with 14C-KIH-2023 were investigated. More than 90% of the dosed radioactivity was detected in the excreta within 96 hr after dosing. Level of the radioactivity in the blood of male and female rats reached maxima at 2 and 1 hr after dosing, respectively, and then decreased rapidly to about a half level of maxima (C1/2). The radioactivity of tissues was lower at 96 hr after dosing than that at C1/2-time. Most of the radioactivity in the urine, feces, liver and plasma was detected as unchanged KIH-2023. The major radioactive compounds excreted into the bile were KIH-2023 and its glucuronide. Repeated oral administration of KIH-2023 for 15 days gave similar results from the single oral one in the excretion, tissue distribution and metabolism of 14C-KIH-2023.

Parent and 5 metabolites were identified in the excreta of male and female /rats/ following /IV or orally/ administered [14Cpy]-bispyribac-sodium and parent and 3 metabolites identified with [14C-Bn]-bispyribac-sodium administration. The parent compound, bispyribac-sodium, was the major component identified in the feces (37-69% of the dose) and urine (5-41%of the dose), in both sexes. Metabolites identified in the excreta constituted 8.3-14.6% and unknown metabolites constituted 0.7-5.2% of the dose.|One Fischer 344 rat/sex/group was dosed by either oral gavage or intravenous injection with 100 mg/kg of (14)C Bispyribac (KIH-2023, specific activity: 1.50 GBq/mmol, radiochemical purity: 98.2%) (label on the 2nd carbon of the pyrimidine ring). Technical grade Bispyribac (KIH-2023, purity: 95.2%) was used to supplement the dosing preparations. ... Demethylation of the parent compound was the predominant metabolic process identified.|Groups of Fischer 344 rats were dosed orally by gavage or by intravenous injection with bis-(pyrimidine-2-(14)C) Bispyribac (KIH-2023, radiochemical purity: 98.3%, specific activity: 87.0 :Ci/mg) ((14)C (Py) Bispyribac) or U-(benzene-(14)C) Bispyribac (radiochemical purity: >99%, specific activity: 50 :Ci/mg) (14)C (Bn) Bispyribac). In Groups 1A, B, C and D, 5 animals/sex/group were dosed orally with 30 mg/kg of either (14)C (Py) Bispyribac (A and C) or (14)C (Bn) Bispyribac (B and D). For Groups 2 A and B, 5 animals/sex/group were dosed daily by oral gavage with 30 mg/kg of Bispyribac, technical grade (purity: 97.2%) for 14 days, followed a dose of 30 mg/kg of either (14)C (Py) Bispyribac (A) or (14)C (Bn) Bispyribac (B). For Groups 3A, B, C and D, 5 animals/sex/group were dosed orally by gavage with 600 mg/kg of either (14)C (Py) Bispyribac (A and C) or (14C) (Bn) Bispyribac (B and D). For Groups 4A, B, C and D, five animals/sex/group received intravenous injections of 30 mg/kg of either (14)C (Py) Bispyribac (A and C) or (14)C (Bn) Bispyribac (B and D). ... The test material was metabolized by cleavage of the ether linkage between the benzene and pyrimidine rings and removal of the methyl groups from the pyrimidine moieties. The position of the radiolabel did not alter the metabolic profile. ...

Groups of Fischer 344 rats were dosed orally by gavage or by intravenous injection with bis-(pyrimidine-2-(14)C) Bispyribac (KIH-2023, radiochemical purity: 98.3%, specific activity: 87.0 :Ci/mg) ((14)C (Py) Bispyribac) or U-(benzene-(14)C) Bispyribac (radiochemical purity: >99%, specific activity: 50 :Ci/mg) (14)C (Bn) Bispyribac). In Groups 1A, B, C and D, 5 animals/sex/group were dosed orally with 30 mg/kg of either (14)C (Py) Bispyribac (A and C) or (14)C (Bn) Bispyribac (B and D). For Groups 2 A and B, 5 animals/sex/group were dosed daily by oral gavage with 30 mg/kg of Bispyribac, technical grade (purity: 97.2%) for 14 days, followed a dose of 30 mg/kg of either (14)C (Py) Bispyribac (A) or (14)C (Bn) Bispyribac (B). For Groups 3A, B, C and D, 5 animals/sex/group were dosed orally by gavage with 600 mg/kg of either (14)C (Py) Bispyribac (A and C) or (14C) (Bn) Bispyribac (B and D). For Groups 4A, B, C and D, five animals/sex/group received intravenous injections of 30 mg/kg of either (14)C (Py) Bispyribac (A and C) or (14)C (Bn) Bispyribac (B and D). ... The pharmacokinetic parameters (calculated for only the 30 mg/kg doses) were as follows: males, t1/2-28.4 to 37.9 hours, tmax-0.29 to 0.31 hours, females, t1/2-28.0 to 37.1 hrs, tmax-0.32 to 0.36 hrs.

/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/|/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/|/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/

2,6-bis(4,6-dimethoxypyrimidin-2-yloxy)benzoic acid

Soluble powder, concentrate suspension /Bispyribac-sodium/|Regiment Herbicide (Valent U.S.A. Corporation) Bispyribac-sodium 80% /Bispyribac-sodium/|Velocity Herbicide (Valent U.S.A. Corporation) Bispyribac-sodium 80% /Bispyribac-sodium/|Velocity SG Herbicide (Valent U.S.A. Corporation) Bispyribac-sodium 17.6% /Bispyribac-sodium/|For more Formulations/Preparations (Complete) data for Bispyribac (6 total), please visit the HSDB record page.

The WHO Recommended Classification of Pesticides by Hazard identifies bispyribac (technical grade) as Class III: slightly hazardous; Main Use: herbicide.

Adequate enforcement methodology (high-performance liquid chromatography (HPLC) with tandem mass spectroscopy detection (MS/MS)) is available to enforce the tolerance expression. /Bispyribac-sodium/|In soil by GC with MSD. In water by HPLC with UV detection. Metabolites in soil or water by HPLC with UV detection.

Agrochemicals -> Herbicides